MMJ Recs

DECEMBER 28, 2023

As the medical community delves into the therapeutic potential of cannabis, certain health conditions have emerged as primary candidates for its prescription. THC, the psychoactive component of cannabis, has analgesic properties that can help manage chronic pain conditions, such as neuropathic pain and arthritis.

Conditions 98

Conditions Chronic Pain Epilepsy Research and Development 98

Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

JULY 19, 2021

There is an urgent need for objective, scientifically sound and robust clinical trials to support medicinal cannabis and psychedelics (psilocybin, MDMA, LSD, Ketamine). Extensive early phase experience with appropriate safety oversight and early phase clinic.

Clinical Trials 98

Clinical Trials Research and Development Hybrid Medicine 98

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 52

Clinical Trials Data Patients THC 52

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma’s objective is to create and leverage a proprietary drug development platform in collaboration with an artificial intelligence and machine learning group to identify new bioactive compounds within the cannabis plant that interact with certain gene targets responsible for specific disease states and conditions.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. From its anti-inflammatory properties to its ability to alleviate pain, CBD shows promise in addressing various health conditions.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

AUGUST 22, 2021

Silo Pharma’s notice of allowance paves the way toward clinical trials for its psychedelics delivery platform using homing peptides. Unlike competitors administering generic psychedelics, the company’s patented technology could improve safety and efficacy while guaranteeing market exclusivity. Silo Pharma Inc. Silo Pharma Inc.

Clinical Trials 105

Clinical Trials Research and Development Safety Treatment 105

Veriheal

AUGUST 28, 2023

And it further reinforces the need to carry out clinical trials to determine the safety and efficiency of using psilocybin to treat OCD. Current approaches to treat this condition are helpful but do not always provide full relief. In some cases, these patients are prone to depression and suicide.

Treatment 56

Treatment Clinical Trials Therapy Research and Development 56

Veriheal

AUGUST 22, 2022

Clinical trials into cannabis’ potential as an opioid replacement are well underway in South Africa. Quite frankly, the clinical trials couldn’t have come at a better time. About the Opioid Epidemic. I don’t think it works for severe pain. Together, they work very well.

Clinical Trials 111

Clinical Trials Chronic Pain Hydroponic Strains 111

Cannabis Law Report

NOVEMBER 19, 2021

“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.” ” About PsyBio Therapeutics Corp.

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

AUGUST 5, 2021

Psychedelics are quickly emerging as alternative methods of treatment for mental illnesses and neurodegenerative conditions — particularly in countries such as Canada. What’s more, over the coming years psychedelics will continue to gain acceptance for treating these conditions which will also contribute to that market growth.

Extraction 105

Extraction Clinical Trials Research and Development Pharmaceutical 105

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Systematic review and meta-analysis were performed to examine the efficacy and safety of MCs treatment among children.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

JUNE 19, 2022

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials. However, we need rigorous clinical trials to ensure that this promise is realised. June 14, 2022 02:00 AM Eastern Daylight Time.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

The Cannigma

MARCH 7, 2022

CBN’s ability to target CB2 receptors, in comparison to THC (which prefers the CB1 receptor), gives it better credibility in treating autoimmune conditions such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. What can the current clinical trials tell us?

THC 140

THC Sleep Clinical Trials Cannabinoids 140

Medicinal Marijuana Association

FEBRUARY 11, 2024

You may have heard whispers of cannabis being used to address a specific eye condition, but what does the research truly reveal about its effectiveness? Glaucoma: Understanding the Condition Understanding glaucoma is crucial for recognizing its symptoms and seeking timely treatment.

Treatment 52

Treatment Blood Pressure Conditions Clinical Trials 52

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

AUGUST 3, 2021

There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Canna Care Docs

OCTOBER 3, 2023

One study supporting the efficacy of cannabinoids is in the Journal of Pain and Symptom Management, titled, “Multicenter, Double-Blind, Randomized, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract in Patients with Intractable Cancer-Related Pain.”

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

The Blunt Truth

DECEMBER 23, 2020

These companies faced administrative actions by the FTC for “making a wide range of scientifically unsupported claims about their ability to treat serious health conditions,” such as cancer, Alzheimer’s disease, and pain relief. The warning letters address the illegal marketing of unapproved CBD products claiming to treat medical conditions.

CBD 103

CBD Food Safety Clinical Trials 103

The Cannigma

FEBRUARY 2, 2021

Of these consumers, over half said the drug had a beneficial clinical effect on their condition. As medicinal cannabis treatments are now legal in many parts of the world, naturally, there is a growing interest in whether the products can treat neurological conditions like Parkinson’s disease. Parkinson’s disease and cannabis.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Cannabis Law Report

OCTOBER 13, 2021

Continued innovation, as demonstrated by our expanding IP portfolio, positions Cybin as a leading innovator in the development of putative psychedelic treatments for a variety of mental health conditions,” said Doug Drysdale, the company’s CEO. Vigorous scientific research and clinical trials are needed. About Cybin.

Clinical Trials 52

Clinical Trials Research and Development Treatment Conditions 52

Cannabis Law Report

JUNE 21, 2021

Most of the data came from five states that list these indications as qualifying conditions for the use of medical cannabis. Taking the doctor-patient use of RYAH devices one step further, organizations conducting clinical trials are finding value in the company’s offerings.

Data 105

Data Clinical Trials Research and Development Indica 105

MMJ Recs

NOVEMBER 20, 2023

Both THC and CBD have demonstrated analgesic properties, making them valuable for managing chronic pain conditions such as arthritis, fibromyalgia, and cancer-related pain. Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

MMJ Recs

NOVEMBER 30, 2023

Medical marijuana has shown potential in treating a wide range of medical conditions, including epilepsy. Epilepsy and MMJ: A Patient’s Perspective For individuals living with epilepsy, finding an effective treatment is often a journey marked by trial and error.

Epilepsy 105

Epilepsy Treatment Patients Strains 105

PrestoDoctor

OCTOBER 11, 2023

In this post, we will explore the benefits of CBD-rich cannabis for treating ASD, the science behind it, and how it can help break barriers for individuals with this condition. ASD and its Social Symptoms Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition that affects individuals in various ways.

CBD 52

CBD Research and Development Clinical Trials Treatment 52

Cannabis Law Report

NOVEMBER 22, 2019

“As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development. 561-627-9455. 917-562-9610.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

JANUARY 19, 2022

He understands that treatment and education for conditions such as Autism and Alzheimer’s disease have the potential to positively impact millions of lives. We look forward to his guidance in helping us bring new, THC-based investigational medications into FDA approved clinical trials. www.igcinc.us , www.igcpharma.com.

Clinical Trials 52

Clinical Trials Research and Development Education Therapy 52

Cannabis Law Report

OCTOBER 9, 2021

A coalition of Pennsylvania lawmakers introduced a bill this week that’s meant to promote research into the therapeutic potential of psilocybin mushrooms for mental health conditions such as post-traumatic stress disorder (PTSD)—the latest example of how the psychedelics reform movement is gaining momentum. Led by Rep.

Therapy 52

Therapy Clinical Trials Treatment Legislation 52

Cannabis Law Report

JULY 7, 2021

We remain encouraged as we continue our evaluations of MYMD-1 for efficacy and safety – especially as studies continue to suggest we may be able to address many of the concerns that are associated with the current drugs on the market today in these disease areas.”. President, Director and Chief Medical Officer of MyMD. “We

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Cannabis Law Report

JULY 29, 2021

Our evidence-based scientific approach has enabled us to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

DECEMBER 26, 2021

The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. ” In Vivo Toxicity Assays Completed.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Veriheal

JANUARY 5, 2023

A randomized, double-blind, cross-over trial of cannabis recently published by Research Gate explored whether or not cannabidiol (CBD) — the primary non-intoxicating constituent of cannabis and hemp — improves or reduces the cannabis safety. . About the Study Into CBD’s Influence on Cannabis Safety.

Clinical Trials 82

Clinical Trials Safety Consumption CBD 82

Cannabis Law Report

FEBRUARY 9, 2022

There’s also concern about a rare condition known as wood lover’s paralysis , a condition that produces muscle weakness a few hours after hallucinogenic mushrooms are consumed. Scientists don’t know why this condition occurs, but it isn’t believed to happen with Psilocybe cubensis. Other species might be introduced later.

Clinical Trials 52

Clinical Trials Microdosing Safety Conditions 52

The Cannigma

AUGUST 31, 2021

Barely a quarter of cannabis users trust their doctor to provide them with reliable information about medical cannabis and how to use it to treat their medical or health conditions, according to a recent survey. The respondents ranged in age from 19 to 81, and 50% identified as White, 20% as Latino, 12% as Asian, and 10% as Black.

Education 101

Education Clinical Trials Medicine Policy 101